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Brief Research Reportsparticularly evident among patients with complex lesions.
Efforts should be undertaken to reduce the incidence of
stroke, however, which remains higher in patients
undergoing CABG. Aortic ‘‘no touch’’ off-pump CABG
has been recently proposed as a means of minimizing the
risk of perioperative stroke. The rate of off-pump surgery
varied among the trials included, ranging from 1.8%5 to
63.8%.4 A trend toward an increased rate of stroke was
found among patients undergoing CABG regardless of the
rate of off-pump surgery. No data were available on
manipulation of the ascending aorta or the use of epiaortic
scanning, however, so whether off-pump surgery would
truly be beneficial cannot be evaluated, and further studies
are needed.
Despite these limitations, this meta-analysis demon-
strates a significant reduction in repeated revascularization
with CABG, which outweighs its detrimental increase in
stroke rate. Only first-generation DESs were used in allFrom the Department of Surgery, Columbia University Medical Center,
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New York, NYMechanical circulatory support (MCS) devices have become
more popular in the treatment of cardiogenic shock (CS).
Options for emergency support include venoarterial extra-
corporeal membrane oxygenation, percutaneous ventricular
assist devices (VADs), and surgical VADs. Among MCS
devices, surgical VADs have the advantage of providing
sufficient circulatory support1; however, the standard tech-
nique requires implantation through a median sternotomy.2
Previously, we described a unique configuration of the
CentriMag (Thoratec Corporation, Pleasanton, Calif) left
VAD (LVAD) that allowed rapid off-pump placement
without performing a sternotomy.3 Here we present a seriesof cases of patients who received this external apicoaxillary
LVAD (AA-LVAD) as a bridge to decision.MATERIALS AND METHODS
Our institutional review board approved this study. Between January
2007 and December 2013, a series of 198 patients underwent CentriMag
VAD insertion for CS at our institution. The cases of 7 patients who
received AA-LVADs were reviewed.
Indications
Indications for AA-LVAD placement include patients in CS who require
VAD support but do not meet criteria for durable MCS device implantation
at the time of evaluation. Our default strategy for device therapy in CS is to
insert a short-term biventricular VAD, so this technique is reserved for
those who can succeed with isolated LVAD support. Patients with CS
who have peripheral vascular disease that precludes the use of a
percutaneous MCS may also be considered for this support. Patients are
excluded if there are mechanical obstacles to cannulation of their axillary
artery or left ventricular apex.
Technique
The details of AA-LVAD implantation are described elsewhere.3
Briefly, after intubation, the axillary artery (right or left) is exposed through
a small infraclavicular incision, and the left ventricular apex is exposed
through a left anterior thoracotomy. Heparin of 5 to 10,000 units is given.
An 8-mm Dacron polyester fabric graft is sewn end to side to the
axillary artery, and the arterial cannula (24F EOPA; Medtronic, Inc,gery c November 2014




(No.) MCS CVVH Etiology of heart failure
INTERMACS
level LV cannula EBL (mL) PRBCs (units)
1 50 M 2 None No NIDCM 1 40F — 0
2 52 F 1 None No ICM 1 34F 300 2
3 62 M 2 ECMO Yes ICM 1 36F 200 1
4 28 F 3 None No Rheumatic disease, ICM 1 24F 300 4
5 53 M 2 ECMO No Rheumatic disease 1 32F 25 0
6 68 M 1 IABP No ICM 1 36F 50 0
7 65 M 1 IABP No ICM 1 36F 50 0
MCS, Mechanical circulatory support; CVVH, continuous venovenous hemofiltration; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support;
LV, left ventricle; EBL, estimated blood loss; PRBCs, packed red blood cells; NIDCM, nonischemic dilated cardiomyopathy (secondary to congenital bicuspid aortic valve);
ICM, ischemic cardiomyopathy; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump.
Brief Research ReportsMinneapolis, Minn) is inserted into the graft. Double purse-string
sutures buttressed with felt pledgets are placed at the left ventricular
apex, and the inflow cannula (Table 2) is inserted 2.5 to 3 cm into the
left ventricle through a stab wound. The cannulas are then connected to a
CentriMag circuit. No cardiopulmonary bypass support is required.
Heparin is started (goal of a partial thromboplastin time of 60-80 seconds)
when chest tube output is minimal. Blood pressure is monitored
through an arterial line in the contralateral upper extremity when
possible. If a femoral line is required, it is revised before the patient
reaches the stage of ambulation. The patients participate in ambulatory
rehabilitation when feasible and, when their general condition is stable,
undergo next step evaluation for explantation, device exchange, or heart
transplantation.RESULTS
Seven patients received AA-LVADs through the right
axillary artery. The average (SD) age was 54  12 years
(range, 28-68 years). All were in CS as a result of acute
decompensated heart failure, and all had had previous
sternotomies. At the time of implantation, 4 patients
were receiving MCS with either an intra-aortic balloon
pump (IABP) or venoarterial extracorporeal membrane
oxygenation (Table 1). The IABP was removed within 24
hours after the operation. Among the 3 patients who were
not receiving MCS, IABP was contraindicated in 1 case
because of a type B aortic dissection, and attempts at
IABP insertion failed in the other 2 cases because of
incompatible vasculature.TABLE 2. Outcomes
Duration (d)
Pressor support
at 72 h (No. of drips) CVA Infection
1 48 1 SAH PNA
2 14 1 None None
3 17 4 VBI None
4 56 1 SAH PNA, Clostridium diffic
5 7 3 None None
6 22 0 None None
7 20 1 None None
CVA, Cerebrovascular accident; SAH, subarachnoid hemorrhage; PNA, pneumonia; OHT,
BTT, bridge to transplant; VBI, vertebrobasilar insufficiency; DT, destination therapy.
The Journal of Thoracic and CarAll insertions were done off pump with minimal blood
loss (Table 1). The average flow during the first 72 hours
was 4  0.9 L/min. Five patients (71%) were weaned
from mechanical ventilation within 72 hours (3 within 24
hours, 2 within 48 hours). Four patients participated in
ambulatory rehabilitation, and 2 were able to be out of bed
to a chair. Four patients (57%) were free of any major com-
plications. Two patients had infections develop. Three had
neurologic complications, although only 1 of those was ma-
jor (Table 2). Two patients had bleeding complications
requiring reoperation. One patient underwent a colectomy
for colon cancer. One patient had clinically observed hyper-
perfusion of the right upper extremity but did not require
revision of the arterial outflow tract. There were no other
adverse events associated with the axillary cannulation.
Five patients (71%) survived to the next step: 1 to
transplant and 4 to durable LVAD implantation (2 as
destination therapy and 2 as bridge to transplant). Two
patients died of multisystem organ failure (Table 2).DISCUSSION
Although recent studies have shown the benefit of early
and aggressive use of MCS devices in patients with critical
heart failure,4 durable MCS devices are known to result in
both poor operative mortality and poor long-term outcomes
in this same population.5 Percutaneous devices are anReoperation Survival to discharge Primary outcome
Bleeding from axilla Yes OHT
None Yes HMII BTT
None No Death
ile Hemothorax 32 No Death
None Yes HMII DT
Colectomy Yes HMII BTT
None Yes HMII DT
orthotopic heart transplant; HMII, Heartmate II (Thoratec Corp, Pleasanton, Calif);
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Brief Research Reportsappealing option, yet they may be too limited in flow and
durability.2 The AA-LVAD combines the benefit of a
relatively quick insertion with sufficient circulatory
support for restoration of end-organ function4 and avoids
the hazards of resternotomy and invasive surgery.
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J Thorac Cardiovasc Surg. 2003;125:855-62.Are preoperative B-type natriuretic peptide levels associated with
outcome after pulmonary artery banding and the double switch
operation in patients with congenitally corrected transposition of
the great arteries: A pilot studyDanton S. Char, MD,a Stephen C. Shiboski, PhD,b Frank L. Hanley, MD,c and Jeffrey R. Fineman, MD,d
Stanford and San Francisco, CalifPulmonary artery banding (PAB) for ventricular training fol-
lowed by the double switch operation (DSO) is an attractive
surgical option for suitable patients with congenitally
corrected transposition of the great arteries (ccTGA). After
repair, the systemic circulation is supported by the morpho-
logic left ventricle (LV). Adoption of DSO was driven by
the poor natural history of the systemic right ventricle (RV)
and successful outcomes with DSO have been reported since
the mid-1990s.1 Although mortality after these operations is
low with careful patient selection, the accurate prediction of
adverse postoperative outcomes is difficult, and there remains
an unpredictable risk of morbidity, takedown or reoperation.2
Recent studies have demonstrated that perioperative
changes in B-type natriuretic peptide (BNP) levels maypredict postoperative morbidity and mortality after surgery
for the repair or palliation of congenital cardiac defects.3
However, the potential usefulness of preoperative BNP
levels as predictors of postoperative outcomes in patients
undergoing repair for ccTGA has not been investigated.
This pilot study hypothesized that preoperative BNP levels
could be associatedwith unexpected outcomes after PAB and
DSO in patients otherwise deemed to be suitable operative
candidates on the basis of standard preoperative clinical,
echocardiographic, and hemodynamic assessments.
MATERIALS AND METHODS
Design and Participants
A pilot prospective cohort study was undertaken at Lucile Packard
Children’s Hospital Heart Center from November 2011 to November
2013. Eligible participants included all patients with ccTGA undergoing
either PAB or DSO. Management followed standard institutional practices.
Informed consent from the patients or their guardians was obtained before
enrollment. The Stanford University Medical Center Institutional Review
Board approved the study (IRB 22458).
Blood samples were obtained from a venous or arterial catheter less than
24 hours preoperatively and were assayed using a commercially available
fluorescence immunoassay (Triage Meter Plus; Biosite Diagnostic, San
Diego, Calif).
Outcome
The end point was a composite of adverse outcomes including death,
cardiac arrest, need for extracorporeal cardiopulmonary life support or
emergency reoperation.
Analysis
The 2-sided Fisher exact test was used to evaluate the association
between increased BNP level (>300 pg/mL) and the binary compositegery c November 2014
